ANI Pharmaceuticals announced the launch of Levofloxacin Oral Solution, a generic version of the Reference Listed Drug Levaquin. The current annual U.S. market for Levofloxacin Oral Solution is approximately $7.1M, according to latest estimates from IQVIA/IMS Health, a leading healthcare data and analytics provider.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals initiated with an Overweight at Capital One
- ANI Pharmaceuticals: Current Performance Insights Revealed
- ANI Pharmaceuticals price target raised to $77 from $70 at Guggenheim
- ANI Pharmaceuticals price target raised to $83 from $73 at H.C. Wainwright
- ANI Pharmaceuticals price target raised to $80 from $72 at Truist
